RTS,S

RTS,S
Vaccine description
TargetP. falciparum; to a lesser extent Hepatitis B
Vaccine typeProtein subunit
Clinical data
Trade namesMosquirix
Routes of
administration		intramuscular injection (0.5 mL)[1]
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
UNII
A poster advertising trials of the RTS,S vaccine[2]

RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands.[3][4] 18 million doses have been allocated for 2023-2025.[5] It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years.[3] The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.[3][6]

  1. ^ Cite error: The named reference ema was invoked but never defined (see the help page).
  2. ^ "RTS,S Malaria Vaccine: 2019 Partnership Award Honoree". YouTube. Global Health Technologies Coalition. 15 November 2019. Retrieved 6 October 2021.
  3. ^ a b c Cite error: The named reference npr-052022 was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference unicef-082022 was invoked but never defined (see the help page).
  5. ^ "18 million doses of first-ever malaria vaccine allocated to 12 African countries for 2023–2025: Gavi, WHO and UNICEF".
  6. ^ Wadman M (24 October 2023). "First malaria vaccine slashes early childhood mortality". Science.